CAR-T Cell Therapy in China
Why Choose China for CAR-T Therapy?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is the most advanced immunotherapy available for relapsed or refractory blood cancers — but it costs €300,000–€500,000 per course in Europe or the United States, where access is also limited to a handful of specialist centres. China's NMPA has approved domestically developed CAR-T products, and Ruijin Hospital in Shanghai operates one of the world's most experienced CAR-T programmes. European patients can access the same class of treatment at 60–80% lower cost.
What's Included
- Ruijin Hospital (Shanghai) is Asia's leading CAR-T centre — among the world's most experienced by case volume
- NMPA-approved CAR-T products for relapsed/refractory B-cell NHL, acute lymphoblastic leukaemia, and multiple myeloma
- 60–80% cost savings versus European or US treatment courses
- Active clinical trials offering access to next-generation CAR-T constructs not yet available in Europe
- Dedicated haematology wards with isolation facilities for safe CAR-T infusion and monitoring
Cost Comparison
| Location | Typical Cost |
|---|---|
| China (Grade 3A Hospital) | €30,000 – €80,000 |
| Europe (Private) | €300,000 – €500,000+ (where available) |
Costs are indicative ranges and vary by hospital, procedure complexity, and individual case. Exact quotes provided after medical record review.
Ready to get a quote?
Free, no-obligation assessment — personalised roadmap within 24 hours.
How does the process work?
From initial assessment to returning home — we guide every step.
See the full patient journey →Frequently Asked Questions
What blood cancers can be treated with CAR-T therapy in China?
NMPA-approved CAR-T products in China target relapsed or refractory B-cell non-Hodgkin lymphoma (including diffuse large B-cell lymphoma), acute lymphoblastic leukaemia (B-ALL), and multiple myeloma. Eligibility is assessed individually based on prior treatment history, disease characteristics, and performance status. Ruijin Hospital's haematology team reviews medical records in advance to confirm suitability.
Why is CAR-T therapy so much cheaper in China than in Europe?
Several domestically developed CAR-T products have received NMPA approval in China — they are not licensed versions of Western pharmaceutical products and are therefore not subject to the same pricing structures. Manufacturing economics and healthcare price regulation further reduce costs. The clinical quality of approved products at Ruijin Hospital is validated by published outcomes data in peer-reviewed oncology journals.
How does Ruijin Hospital's CAR-T programme compare internationally?
Ruijin Hospital is China's preeminent haematology centre and one of the world's most experienced in CAR-T cell therapy. It holds Grade 3A, JCI, and DNV DIAS (2025) accreditation — the only hospital in mainland China with all three. Its haematology outcomes data are published in leading international oncology journals including Blood and Nature Medicine.
What is the process for a European patient seeking CAR-T therapy at Ruijin?
The process begins with a remote pre-assessment: medical records, pathology reports, treatment history, and imaging are reviewed by Ruijin's haematology team. If eligibility is confirmed, the patient travels to Shanghai for T-cell harvesting (leukapheresis), waits 2–4 weeks during CAR-T manufacturing, then returns for infusion and a monitoring period of 2–4 weeks. Our coordinators manage every stage of this process.
Ready to Explore Your Options?
Submit a free assessment and receive a personalised treatment roadmap within 24 hours.